[
  {
    "patent_id": "US403982A1",
    "title": "heroin fever reduction novel formulation and delivery mechanism",
    "assignee": "Generic Pharma Co.",
    "inventors": [
      "Amit Sharma",
      "Carlos Gomez"
    ],
    "filing_year": 2021,
    "publication_year": 2024,
    "expiry_year": 2036,
    "therapeutic_area": "Fever reduction",
    "abstract": "This invention relates to an improved pharmaceutical formulation of heroin, designed for enhanced fever reduction. The composition includes modified excipients which result in improved bioavailability, reduced first-pass metabolism, and superior therapeutic control. The formulation offers manufacturing advantages and potential clinical benefit compared to existing products.",
    "status": "Active",
    "pdf_link": "https://patents.google.com",
    "url": "https://patents.google.com"
  },
  {
    "patent_id": "US706129A1",
    "title": "heroin inflammation novel formulation and delivery mechanism",
    "assignee": "Generic Pharma Co.",
    "inventors": [
      "Priya Nair",
      "Rajesh Kumar"
    ],
    "filing_year": 2017,
    "publication_year": 2022,
    "expiry_year": 2030,
    "therapeutic_area": "Inflammation",
    "abstract": "This invention relates to an improved pharmaceutical formulation of heroin, designed for enhanced inflammation. The composition includes modified excipients which result in improved bioavailability, reduced first-pass metabolism, and superior therapeutic control. The formulation offers manufacturing advantages and potential clinical benefit compared to existing products.",
    "status": "Expired",
    "pdf_link": "https://patents.google.com",
    "url": "https://patents.google.com"
  },
  {
    "patent_id": "US341316A1",
    "title": "heroin combination therapy novel formulation and delivery mechanism",
    "assignee": "Dr. Reddyâ€™s Laboratories",
    "inventors": [
      "Sara Kim",
      "Carlos Gomez"
    ],
    "filing_year": 2019,
    "publication_year": 2021,
    "expiry_year": 2029,
    "therapeutic_area": "Combination therapy",
    "abstract": "This invention relates to an improved pharmaceutical formulation of heroin, designed for enhanced combination therapy. The composition includes modified excipients which result in improved bioavailability, reduced first-pass metabolism, and superior therapeutic control. The formulation offers manufacturing advantages and potential clinical benefit compared to existing products.",
    "status": "Active",
    "pdf_link": "https://patents.google.com",
    "url": "https://patents.google.com"
  },
  {
    "patent_id": "US252959A1",
    "title": "heroin extended-release technology novel formulation and delivery mechanism",
    "assignee": "Pfizer Inc.",
    "inventors": [
      "Priya Nair",
      "Anna Petrova"
    ],
    "filing_year": 2016,
    "publication_year": 2018,
    "expiry_year": 2033,
    "therapeutic_area": "Extended-release technology",
    "abstract": "This invention relates to an improved pharmaceutical formulation of heroin, designed for enhanced extended-release technology. The composition includes modified excipients which result in improved bioavailability, reduced first-pass metabolism, and superior therapeutic control. The formulation offers manufacturing advantages and potential clinical benefit compared to existing products.",
    "status": "Pending",
    "pdf_link": "https://patents.google.com",
    "url": "https://patents.google.com"
  },
  {
    "patent_id": "US239284A1",
    "title": "heroin extended-release technology novel formulation and delivery mechanism",
    "assignee": "Pfizer Inc.",
    "inventors": [
      "Priya Nair",
      "Emily Zhang"
    ],
    "filing_year": 2015,
    "publication_year": 2022,
    "expiry_year": 2027,
    "therapeutic_area": "Extended-release technology",
    "abstract": "This invention relates to an improved pharmaceutical formulation of heroin, designed for enhanced extended-release technology. The composition includes modified excipients which result in improved bioavailability, reduced first-pass metabolism, and superior therapeutic control. The formulation offers manufacturing advantages and potential clinical benefit compared to existing products.",
    "status": "Expired",
    "pdf_link": "https://patents.google.com",
    "url": "https://patents.google.com"
  },
  {
    "patent_id": "US265757A1",
    "title": "heroin inflammation novel formulation and delivery mechanism",
    "assignee": "Generic Pharma Co.",
    "inventors": [
      "Amit Sharma",
      "Anna Petrova"
    ],
    "filing_year": 2016,
    "publication_year": 2018,
    "expiry_year": 2038,
    "therapeutic_area": "Inflammation",
    "abstract": "This invention relates to an improved pharmaceutical formulation of heroin, designed for enhanced inflammation. The composition includes modified excipients which result in improved bioavailability, reduced first-pass metabolism, and superior therapeutic control. The formulation offers manufacturing advantages and potential clinical benefit compared to existing products.",
    "status": "Expired",
    "pdf_link": "https://patents.google.com",
    "url": "https://patents.google.com"
  }
]